News | October 23, 2025
Ipsen to acquire ImCheck Therapeutics to strengthen oncology pipeline
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Expanding US operations to address the increased demand for API development and manufacturing
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Subscribe To Our Newsletter & Stay Updated
